CN102423295B - 一种含有长春西汀的小容量注射液组合物及其制备方法 - Google Patents
一种含有长春西汀的小容量注射液组合物及其制备方法 Download PDFInfo
- Publication number
- CN102423295B CN102423295B CN 201110181379 CN201110181379A CN102423295B CN 102423295 B CN102423295 B CN 102423295B CN 201110181379 CN201110181379 CN 201110181379 CN 201110181379 A CN201110181379 A CN 201110181379A CN 102423295 B CN102423295 B CN 102423295B
- Authority
- CN
- China
- Prior art keywords
- injection
- vinpocetine
- acidic amino
- amino acid
- small volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 59
- 239000007924 injection Substances 0.000 title claims abstract description 59
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 title claims abstract description 56
- 229960000744 vinpocetine Drugs 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title abstract description 25
- 239000000203 mixture Substances 0.000 title abstract description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 56
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000002378 acidificating effect Effects 0.000 claims abstract description 32
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 28
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008215 water for injection Substances 0.000 claims abstract description 19
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 239000000600 sorbitol Substances 0.000 claims abstract description 17
- -1 amino acid salts Chemical class 0.000 claims abstract description 16
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 5
- 229940024606 amino acid Drugs 0.000 claims description 31
- 235000001014 amino acid Nutrition 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 238000005352 clarification Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 7
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 6
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000003610 charcoal Substances 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 230000005587 bubbling Effects 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 229960003646 lysine Drugs 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims 4
- 238000005516 engineering process Methods 0.000 abstract description 6
- 238000010253 intravenous injection Methods 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 26
- 206010018910 Haemolysis Diseases 0.000 description 13
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 13
- 230000008588 hemolysis Effects 0.000 description 13
- 229960002726 vincamine Drugs 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
样品 | 原料药有关物质 | 灌封后有关物质 | 灭菌后有关物质 |
a | 0.027% | 0.028% | 0.031% |
b | 0.027% | 0.035% | 0.045% |
c | 0.027% | 0.045% | 0.062% |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110181379 CN102423295B (zh) | 2011-06-30 | 2011-06-30 | 一种含有长春西汀的小容量注射液组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110181379 CN102423295B (zh) | 2011-06-30 | 2011-06-30 | 一种含有长春西汀的小容量注射液组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102423295A CN102423295A (zh) | 2012-04-25 |
CN102423295B true CN102423295B (zh) | 2013-03-13 |
Family
ID=45957386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110181379 Active CN102423295B (zh) | 2011-06-30 | 2011-06-30 | 一种含有长春西汀的小容量注射液组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102423295B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066244A (zh) * | 2006-09-28 | 2007-11-07 | 郑州羚锐制药有限公司 | 长春西汀小容量注射剂及其制备工艺 |
CN101889978A (zh) * | 2010-04-29 | 2010-11-24 | 袁璐 | 含有长春西汀的药用组合物及其制备方法和应用 |
CN102038680A (zh) * | 2010-11-24 | 2011-05-04 | 常建晖 | 一种药用组合物 |
CN102091030A (zh) * | 2011-01-20 | 2011-06-15 | 罗军 | 长春西汀注射液及其制备方法 |
-
2011
- 2011-06-30 CN CN 201110181379 patent/CN102423295B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066244A (zh) * | 2006-09-28 | 2007-11-07 | 郑州羚锐制药有限公司 | 长春西汀小容量注射剂及其制备工艺 |
CN101889978A (zh) * | 2010-04-29 | 2010-11-24 | 袁璐 | 含有长春西汀的药用组合物及其制备方法和应用 |
CN102038680A (zh) * | 2010-11-24 | 2011-05-04 | 常建晖 | 一种药用组合物 |
CN102091030A (zh) * | 2011-01-20 | 2011-06-15 | 罗军 | 长春西汀注射液及其制备方法 |
Non-Patent Citations (2)
Title |
---|
碳酸氢钠注射液的配伍禁忌;薛芬;《护理实践与研究》;20061231;第3卷(第8期);第37页 * |
薛芬.碳酸氢钠注射液的配伍禁忌.《护理实践与研究》.2006,第3卷(第8期), |
Also Published As
Publication number | Publication date |
---|---|
CN102423295A (zh) | 2012-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113840622B (zh) | 一种稳定的苏金单抗注射剂及其制备方法 | |
CN102552119A (zh) | 一种盐酸氨溴索葡萄糖注射液及其制备方法 | |
CN104586758A (zh) | 一种对乙酰氨基酚注射液及其制备方法 | |
CN103463614B (zh) | 一种阿加曲班注射液及其制备方法 | |
CN105663035A (zh) | 一种盐酸利多卡因注射液及其制备方法 | |
CN102836123A (zh) | 一种含有左乙拉西坦活性成分的注射剂及其制备工艺 | |
CN102228428B (zh) | 一种含有长春西汀的大容量注射液组合物及其制备方法 | |
CN102423295B (zh) | 一种含有长春西汀的小容量注射液组合物及其制备方法 | |
CN104000827B (zh) | 一种含有活性成分盐酸纳美芬的药物组合物 | |
CN103860461B (zh) | 一种含有活性成分盐酸氨溴索的药物组合物 | |
CN102805857B (zh) | 一种复方氨基酸(15)双肽(2)注射液的制备方法 | |
CN104523580A (zh) | 一种肌苷氯化钠注射液及其制备方法 | |
CN103393595B (zh) | 依达拉奉的药物组合物 | |
CN103830171B (zh) | 一种酮咯酸氨丁三醇注射液及其制备方法 | |
CN103202805B (zh) | 一种含有长春西汀的注射用药物组合物及其制备方法 | |
CN102423311B (zh) | 一种奥扎格雷钠注射液及其制备方法 | |
CN105520955A (zh) | 一种羧基麦芽糖铁药用组合物及其制备方法 | |
CN104606130A (zh) | 一种盐酸托烷司琼注射液及其制备方法 | |
CN106214629A (zh) | 一种灯盏花素药物注射制剂稳定性组合物的制备方法 | |
CN103462888B (zh) | 一种取代的β-环糊精包合的长春西汀注射液及其制备方法 | |
CN111265474B (zh) | 一种帕立骨化醇注射液及其制备方法 | |
CN103356478A (zh) | 一种布洛芬注射液组合物及其制备方法 | |
CN107744501A (zh) | 一种汉防己碱的注射用药物组合物 | |
CN103520097B (zh) | 一种扎那米韦注射液及其制备方法 | |
CN106138211A (zh) | 一种提高红茴香药物注射制剂稳定性的注射用药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TONGYUAN PHARMACEUTICAL IND CO., LTD., WUHAN Effective date: 20141225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430071 WUHAN, HUBEI PROVINCE TO: 411228 XIANGTAN, HUNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141225 Address after: 411228 Fenghuang Road, easy Town, Xiangtan County, Hunan Patentee after: HUNAN WUZHOUTONG PHARMACEUTICAL CO., LTD. Address before: 430071 Hubei Province, Wuhan city Wuchang District Road No. 100 3 unit 101 purple Patentee before: Tongyuan Pharmaceutical Ind Co., Ltd., Wuhan |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Small volume injection composition containing vinpocetine and preparation method thereof Effective date of registration: 20200629 Granted publication date: 20130313 Pledgee: China Construction Bank Corporation Xiangtan County sub branch Pledgor: HUNAN WUZHOUTONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980003555 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: No. 219, biquantan Road, Tianyi Economic Development Zone, Xiangtan City, Hunan Province Patentee after: Hunan wuzhoutong Pharmaceutical Co., Ltd Address before: 411228 Fenghuang Road, easy Town, Xiangtan County, Hunan Patentee before: HUNAN WUZHOUTONG PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |